期刊
PHARMACOLOGY & THERAPEUTICS
卷 222, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2020.107791
关键词
Liver fibrosis; PPARs; Aging; Pathogenesis; Therapy target; Inflammation
资金
- National Natural Science Foundation of China [81973481, 81922073]
- Traditional Chinese Medicine Key Scientific Research Fund Project of Zhejiang Province [2018ZY004]
Liver fibrosis is a dynamic wound-healing process associated with the deposition of extracellular matrix produced by myofibroblasts. Activation of HSCs, inflammation, oxidative stress, steatosis, and aging play critical roles in liver fibrosis progression, which is correlated with the regulation of the peroxisome proliferator-activated receptor (PPAR) pathway. PPAR ligands have been explored as potential therapeutic agents for reversing steatohepatitis and liver fibrosis.
Liver fibrosis is a dynamic wound-healing process associated with the deposition of extracellular matrix pro-duced by myofibroblasts. HSCs activation, inflammation, oxidative stress, steatosis and aging play critical roles in the progression of liver fibrosis, which is correlated with the regulation of the peroxisome proliferator-activated receptor (PPAR) pathway. As nuclear receptors, PPARs reduce inflammatory response, regulate lipid metabolism, and inhibit fibrogenesis in the liver associated with aging. Thus, PPAR ligands have been investigated as possible therapeutic agents. Mounting evidence indicated that some PPAR agonists could reverse steatohepatitis and liver fibrosis. Consequently, targeting PPARs might be a promising and novel therapeutic op-tion against liver fibrosis. This review summarizes recent studies on the role of PPARs on the pathogenesis and treatment of liver fibrosis. (c) 2020 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据